Register today for a FREE Webinar on Biosimilars

 

 




MONDAY, DECEMBER 11, 2017

8:00 PM – 8:45 PM ET
7:00 PM – 7:45 PM CT
6:00 PM – 6:45 PM MT
5:00 PM – 5:45 PM PT








PROGRAM AGENDA

Moderator's Presentation 8:00 PM - 8:10 PM ET
Panel Discussion 8:10 PM - 8:35 PM ET
Q&A 8:35 PM - 8:45 PM ET

MODERATOR/PANELISTS

  • Gary R. Lichtenstein, MD, AGAF, University of Pennsylvania (Moderator)
  • Brian G. Feagan, MD, Robarts Research Institution
  • David T. Rubin, MD, AGAF, University of Chicago
  • Kira, Patient Representative

To view moderator and panelist disclosures click here.

TARGET AUDIENCE

Physicians, advanced practice providers (NPs/PAs), and other healthcare professionals caring for IBD patients

EDUCATIONAL OBJECTIVES

  • Understand the evidence currently available on biosimilars for inflammatory bowel diseases
  • Identify approaches to educating and discussing the topic of biosimilars with patients

PHYSICIAN CONTINUING MEDICAL EDUCATION INFORMATION

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education (AACME) to provide continuing medical education for physicians.

The AGA Institute designates this internet live course for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME's Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

FEE INFORMATION
There is no fee for this educational activity.

SUPPORT STATEMENT
This activity is a collaboration of the AGA Institute and the Crohn's & Colitis Foundation. Supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc.